Every March 24, on World TB Day, the world recommits to the global effort to “reach, treat, and cure” all cases of tuberculosis (TB). Since 2004, ICAP has made a significant impact on TB through initiatives to improve case detection and treatment adherence; combat stigma and discrimination; empower health workers; and build strong partnerships with governments to scale up treatment and prevention programs.
When traditional leaders attended an ICAP-supported gay pride parade in Moletsi, Limpopo this past October, it marked an important moment for one of South Africa’s most religious districts, and perhaps a sign that the traditionalist stance against same-sex sexual behavior is waning.
Through the Nursing Education Partnership Initiative, ICAP and its partners in six sub-Saharan African countries that face critical shortages in human resources for health, have graduated over 6,200 nursing and midwifery students and trained almost 1,600 faculty, mentors, and nursing administrators.
ICAP has begun efforts to evaluate the safety and acceptability of a new injectable drug for potential use as pre-exposure prophylaxis (PrEP) for HIV prevention. Long-acting rilpivirine, which will be assessed in healthy women without HIV infection, offers promise as an injectable drug that would be used every several weeks to prevent women from getting HIV infection.
Four years ago, there were almost no cervical cancer screening services available to women in Tanzania and prevention efforts were almost non-existent. Most women received a cancer diagnosis late, when opportunities for successful medical intervention were limited. As a result, cervical cancer was the leading cause of cancer deaths among Tanzanian women. Since then, ICAP has emerged as a critical part of a larger national effort in Tanzania for effective cervical cancer prevention programs.
Join ICAP at the CROI Conference in Seattle, Washington (February 23 – 26, 2015)